Greenwich, CT, February 22, 2013 – Stuart Needleman, President and Chief Operating Officer, Aptuit LLC, announced that the Aptuit team based at The Aptuit Center for Drug Discovery & Development in Verona, Italy, can provide a range of integrated preclinical and clinical capabilities to evaluate the anti-neurodegenerative effects of small molecules and biological drugs.
“While there are a few CROs that provide activities in neurodegenerative diseases such as Alzheimer’s and Parkinson’s, they are unable to offer Aptuit’s integrated approach, significantly combining in vitro and in vivo preclinical experiments with clinical translational studies,” said Mr. Needleman.
Mr. Needleman explained that Aptuit works in a matrix-team model, frequently in collaboration with experimental medicine centers and Phase I units. He said that these services are particularly important for pharmaceutical companies involved in neurodegenerative diseases and are also valuable to spin off companies that are progressing single compounds in these therapeutic areas.
Aptuit’s team is comprised of preclinical and clinical experts and physicians with long standing
experience in neuroscience research in the early and development stages of the drug discovery process. They represent a broad range of their Integrated Knowledge of in vivo and in vitro pharmacology, DMPK, clinical sciences and pharmaceutical development activities.
Mr. Needleman described Aptuit as being basically different from most of its competitors, saying that Aptuit is uniquely positioned to provide the best of both worlds: the efficiency of a CRO and the capabilities of a large pharma research engine. “Our team has long standing expertise in the neurosciences. Many Aptuit scientists bring a legacy of experience in a large pharma environment, mirroring the neuroscience activities that are the focus of some of our large pharma and biotech customers. Under the leadership of Aptuit scientists, our multidisciplinary team is accustomed to working with clients in an environment of openness and honest communications as we integrate our biological capabilities for the fast development of molecules from bench to patients,” Mr. Needleman concluded.
Maria Garvey, Media Manager, Delfino Marketing, 914-747-1400
Jennifer Demaree, Senior Manager, Marketing & Communications, 203-660-6016
Aptuit LLC provides the most complete set of integrated early to mid-phase development services in the pharmaceutical industry. Drug Design & Discovery, Preclinical Biosciences, API Development and Manufacture, Solid State Chemistry, Drug Product Formulation Development & Manufacture, Sterile Fill Finish, Clinical Sciences, Consulting and Aptuit INDiGOÒ (a program that accelerates drug development) are offered as stand alone or integrated services. Fully integrated drug discovery & development services are available from a single site at The Aptuit Center for Drug Discovery & Development in Verona, Italy. The company maintains five global facilities with approximately 800 employees in Europe and the United States, and has a strategic relationship with Laurus Labs in India. Aptuit LLC is partnered with Welsh, Carson, Anderson & Stowe, one of the world’s leading private equity investors.
For more information about Aptuit, visit www.aptuit.com